Novel therapeutic strategies in acid-related disorders

Bibliography

• RICHARDSON P, HAWKEY CJ, STACK WA: Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs (1998) 56:307–335.
   Google Scholar
• CHIBA N, DE GARA CJ, WILKINSON JM, HUNT RH: Speed of healing and symptom relief in grade II and IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology (1997) 112:1798–1810.
   PubMed Web of Science ®Google Scholar
• TYTGAT GN: Review article: treatment ofmild and severe cases of GERD. Aliment. Pharmacol The]: (2002) 4:73–78.
   Google Scholar
• ROSTOM A, DUBE C, WELLS Get al.: Prevention of NSAID-induced gastroduodenal ulcer. In: The Cochrane Library (Issue 1). Update Software Oxford (2003).
   Google Scholar
• INADOMI JM: On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoeconomics (2002) 20:565–576.
   PubMed Web of Science ®Google Scholar
• VANDERHOFF BT, TAHBOUB PM: Proton pump inhibitors: an update. Am. Pam. Physician (2002) 66:273–280.
   Google Scholar
• SACHS G, SHIN JM, BRIVING C, WALLMARK B, HERSEY S: The pharmacology of the gastric acid pump: the HE-KLATPase. Anna. Rev. Pharmacol Toxicol (1995) 35:277–305.
   PubMed Web of Science ®Google Scholar
• ••An outstanding review of the currentunderstanding of mechanisms controlling acid secretion.
   Google Scholar
• SHIN JM, SACHS G: Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology (2002) 123:1588–1597.
   PubMed Web of Science ®Google Scholar
• •Paper dealing with the irreversibile/ reversibile binding to the proton pump.
   Google Scholar
• GEDDA K, SCOTT D, BESANCON M, LORENTZON P, SACHS G: Turnover of the gastric H+-K+-adenosine triphosphatase a-subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology (1995) 109:1134–1141.
   PubMed Web of Science ®Google Scholar
• SACHS G: Improving on PPI-based therapy of GORD. Ear: j Gastroenterol Hepatol (2001) 13\(Supp1.1):S35–S41.
   Google Scholar
• FITTON A, WISEMAN L: Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs (1996) 51:460–482.
   Google Scholar
• LANGTRY HD, WILDE MI: Omeprazole. A review of its use in Helicobacter pyloriinfection, gastro-oesophageal reflux disease and peptic ulcers induced by non-steroidal anti-inflammatory drugs. Drugs (1998) 56:447–486.
   Google Scholar
• MATHESON Al, JARVIS B: Lansoprazole:an update of its place in the management of acid-related disorders. Drugs (2001) 61:1801–1833.
   PubMed Web of Science ®Google Scholar
• CARSWELL CI, GOA KL: Rabeprazole: an update of its use in acid-related disorders. Drugs (2001) 61:2327–2356.
   PubMed Web of Science ®Google Scholar
• SCOTT LJ, DUNN CJ, MALLARKEY G, SHARPE M: Esomeprazole: a review of its use in the management of acid-related disorders. Drugs (2002) 62:1503–1538.
   PubMed Web of Science ®Google Scholar
• HORN J: The proton-pump inhibitors: similarities and differences. Clin. Ther. (2000) 22:266–280.
   PubMed Web of Science ®Google Scholar
• KROMER W, HORBACH S, LUHMANN R: Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology (1999) 59:57–77.
   PubMed Web of Science ®Google Scholar
• CASTELL DO, KAHRILAS PJ, RICHTER JE et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am. Gastroenterol (2002) 97:575–583.
   PubMed Web of Science ®Google Scholar
• BELL NJ, BURGET D, HOWDEN CW, WILKINSON J, HUNT RH: Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion (1992) 51\(Supp1.1):59–67.
   Google Scholar
• GERSON LB, ROBBINS AS, GARBER A, HORNBERGER J, TRIADAFILOPOULOS G: A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am. Gastroenterol (2000) 95:395–407.
   PubMed Web of Science ®Google Scholar
• ••A study indicating that for patients withmoderate-to-severe GORD, initial treatment with PPIs followed by on-demand therapy is a cost-effective approach.
   Google Scholar
• BYTZER P: On-demand therapy for gastro-oesophageal reflux disease. Ear: Gastroenterol Hepatol (2001)13\(Supp1.1):S19–S22.
   Google Scholar
• PACE F, PALLOTTA S, BIANCHI PORRO G: On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease. Dig. Liv. Dis. (2002) 34:870–877.
   Web of Science ®Google Scholar
• •An updated discussion concerning on-demand-therapy.
   Google Scholar
• TYTGAT GN: Shortcomings of the first-generation proton pump inhibitors. Ear: Gastroenterol Hepatol (2001)13 (Supp1.1):S29–S33.
   Google Scholar
• ROBINSON M: New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur Gastroenterol Hepatol (2001) 13\(Supp1.1):543–547.
   Google Scholar
• TONINI M, VIGNERI S, SAVARINO V, SCARPIGNATO C: Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig. Liv. Dis. (2001) 33:600–606.
   Web of Science ®Google Scholar
• MALFERTHEINER P, MEGRAUD F, O'MORAIN C et al.: Current concepts in the management of Helicobacter pylori infection-the Maastricht 2–2000 Consensus Report. Aliment. Pharmacol Ther. (2002) 16:167–180.
   Google Scholar
• NAESDAL J, WILSON I: Gastro-duodenal protection in an era of cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs. Ear: .1. Gastroenterol Hepatol (2001) 13:1401–1406.
   Google Scholar
• YEOMANS ND: Management of peptic ulcer disease not related to Helicobacter. Gastroenterol Hepatol (2002) 17:488–494.
   Google Scholar
• LEANDRO G, PILOTTO A, FRANCESCHI M, BERTIN T,LICHINO E, DI MARIO F: Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig. Dis. Sci. (2001) 46:1924–1936.
   PubMed Web of Science ®Google Scholar
• HOLTMANN G: Reflux disease: the disorder of the third millennium. Eur j Gastroenterol Hepatol (2001) 13\(Supp1.1):S5–S11.
   Google Scholar
• QUIGLEY EM: Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia or both? Ear. Gastroenterol Hepatol (2001) 13\(Supp1.1):S13–S18.
   Google Scholar
• HOWDEN CW, HENNING JM, HUANG B, LUKASIK N, FRESTON JW: Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am.! Gastroenterol (2001) 96:1704–1710.
   PubMed Web of Science ®Google Scholar
• INADOMI JM, JAMAL R, MURATA GH et al: Step-down management of gastroesophageal reflux disease. Gastroenterology (2001) 121:1095–1100.
   PubMed Web of Science ®Google Scholar
• LIND T, HAVELUND T, LUNDELL L et al: On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment. Pharmacol Ther. (1999) 13:907–914.
   PubMed Web of Science ®Google Scholar
• TALLEY NJ, VENABLES TL, GREEN JR et al.: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Ear: Gastroenterol Hepatol (2002)14:857–863.
   PubMed Web of Science ®Google Scholar
• VAKIL N: Dyspepsia, non-ulcer dyspepsia and Helicobacter pylori. Rev Gastroenterol Disord. (2001) 1:139–146.
   PubMedGoogle Scholar
• STANGHELLINI V, DE PONTI F, DE GIORGIO R, BARBARA G, TOSETTI C, CORINALDESI R: New developments in the treatment of functional dyspepsia. Drugs (2003) In press.
   Google Scholar
• KAMINSKI JJ, DOWEYKO AM: Antiulcer agents. 6. Analysis of the in vitro biochemical and in vivo gastric antisecretory activity of substituted imidazo [1, 2-a]pyridines and related analogues using comparative molecular field analysis and hypothetical active site lattice methodologies. Med. Chem. (1997) 40:427–436.
   Google Scholar
• KROMER W, POSTIUS S, RIEDEL R: Animal pharmacology of reversible antagonism of the gastric acid pump, compared to standard antisecretory principles. Pharmacology (2000) 60:179–187.
   PubMed Web of Science ®Google Scholar
• MARTINEK J, BLUM AL, STOLTE M et al.: Effects of pumaprazole (BY841), a novel reversible proton pump antagonist and of omeprazole, on intragastric acidity before and after cure of Helicobacter pyloriinfection. Aliment. Pharmacol Ther. (1999) 13:27–34.
   PubMed Web of Science ®Google Scholar
• DAVIES NM, ROSETH AG, APPLEYARD CB et al: NO-naproxen versus naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Ailment. Pharmacol Ther. (1997) 11:69–79.
   PubMed Web of Science ®Google Scholar
• TAKEUCHI K, UKAWA H, KONAKA A, KITAMURA M, SUGAWA Y: Effect of nitric oxide-releasing aspirin derivative on gastric functional and ulcerogenic responses in rats: comparison with plain aspirin. I Pharmacol Exp. Ther. (1998) 286:115–121.
   PubMed Web of Science ®Google Scholar